Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  G1 Therapeutics, Inc.    GTHX

G1 THERAPEUTICS, INC.

(GTHX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 07:01am EDT

RESEARCH TRIANGLE PARK, N.C., May 02, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to report financial results for the first quarter of 2019 on Thursday, May 9, 2019 at 4:30 p.m. ET.

The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 7988598. A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib and lerociclib are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Head of Investor Relations/Public Relations
919-907-1944
jmacdonald@g1therapeutics.com

G1 Therapeutics.jpg


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on G1 THERAPEUTICS, INC.
10/01G1 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
09/30G1 THERAPEUTICS : Presents Updated Data at ESMO 2019 from Randomized Phase 2 Tri..
AQ
09/29G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating..
GL
09/28G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Tr..
GL
09/10G1 Therapeutics to Present New Clinical Data Across Pipeline at European Soci..
GL
09/03G1 THERAPEUTICS : to Present at H.C. Wainwright Annual Global Investment Confere..
AQ
08/07G1 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/07G1 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial..
AQ
08/07G1 THERAPEUTICS : Provides Second Quarter 2019 Corporate and Financial Update
AQ
08/06G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in ..
GL
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -128 M
Net income 2019 -122 M
Finance 2019 260 M
Yield 2019 -
P/E ratio 2019 -6,62x
P/E ratio 2020 -5,04x
EV / Sales2019 infx
EV / Sales2020 25,8x
Capitalization 805 M
Chart G1 THERAPEUTICS, INC.
Duration : Period :
G1 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends G1 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 67,33  $
Last Close Price 21,46  $
Spread / Highest target 273%
Spread / Average Target 214%
Spread / Lowest Target 110%
EPS Revisions
Managers
NameTitle
Mark A. Velleca President, Chief Executive Officer & Director
Garry Allen Nicholson Chairman
Terry L. Murdock Chief Operating Officer
Jennifer K. Moses Chief Financial Officer
Jay C. Strum Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
G1 THERAPEUTICS, INC.12.06%805
GILEAD SCIENCES3.77%82 206
VERTEX PHARMACEUTICALS6.35%45 297
REGENERON PHARMACEUTICALS-19.63%32 847
WUXI APPTEC CO., LTD.65.51%20 231
GENMAB32.08%13 665